APLS FY 2023 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$397M+425.8% YoY

Gross Profit

$338M85.2% margin

Operating Income

-$517M-130.4% margin

Net Income

-$529M-133.3% margin

EPS (Diluted)

$-4.45

Cash Flow

Operating Cash Flow

-$595M

Free Cash Flow

-$596M

Stock-Based Comp.

$106M

Balance Sheet

Total Assets

$789M

Total Liabilities

$594M

Stockholders' Equity

$195M

Cash & Equivalents

$351M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$397M	$75M	+425.8%
Gross Profit	$338M	$70M	+384.5%
Operating Income	-$517M	-$595M	+13.0%
Net Income	-$529M	-$652M	+18.9%